Insider Selling: eFFECTOR Therapeutics Inc (NASDAQ:EFTR) Director Sells $58,796.92 in Stock

eFFECTOR Therapeutics Inc (NASDAQ:EFTR) Director Jonathan D. Root sold 7,241 shares of the firm’s stock in a transaction dated Friday, November 19th. The stock was sold at an average price of $8.12, for a total value of $58,796.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of NASDAQ EFTR opened at $7.35 on Thursday. eFFECTOR Therapeutics Inc has a 1-year low of $7.03 and a 1-year high of $40.42. The stock’s fifty day moving average is $13.62.

eFFECTOR Therapeutics (NASDAQ:EFTR) last announced its earnings results on Monday, November 8th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.68. As a group, analysts anticipate that eFFECTOR Therapeutics Inc will post -0.55 earnings per share for the current fiscal year.

Several equities analysts have recently weighed in on the company. Stifel Nicolaus raised eFFECTOR Therapeutics from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Monday, November 8th. Cantor Fitzgerald assumed coverage on eFFECTOR Therapeutics in a report on Monday, September 13th. They set an “overweight” rating and a $50.00 price objective for the company. Mizuho assumed coverage on eFFECTOR Therapeutics in a report on Monday, October 4th. They issued a “buy” rating and a $20.00 target price for the company. JMP Securities assumed coverage on eFFECTOR Therapeutics in a report on Tuesday, September 21st. They issued an “outperform” rating and a $33.00 target price for the company. Finally, Credit Suisse Group assumed coverage on eFFECTOR Therapeutics in a report on Tuesday, October 12th. They issued an “outperform” rating and a $20.00 target price for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, eFFECTOR Therapeutics has a consensus rating of “Buy” and a consensus price target of $28.60.

A number of large investors have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new stake in eFFECTOR Therapeutics during the third quarter worth about $187,000. Jane Street Group LLC acquired a new stake in eFFECTOR Therapeutics during the third quarter worth about $257,000. Geode Capital Management LLC purchased a new position in eFFECTOR Therapeutics during the third quarter worth approximately $337,000. Verition Fund Management LLC purchased a new position in eFFECTOR Therapeutics during the third quarter worth approximately $347,000. Finally, Sectoral Asset Management Inc purchased a new position in shares of eFFECTOR Therapeutics in the third quarter valued at approximately $40,503,000. 70.48% of the stock is currently owned by institutional investors.

About eFFECTOR Therapeutics

Locust Walk Acquisition Corp. entered into a definitive business combination agreement with eFFECTOR Therapeutics Inc

Featured Story: Understanding each part of a balance sheet

Insider Buying and Selling by Quarter for eFFECTOR Therapeutics (NASDAQ:EFTR)

Receive News & Ratings for eFFECTOR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for eFFECTOR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.